Abstract: SA-PO0848
Seroprotection After Influenza Vaccination in Patients with Glomerular Diseases
Session Information
- Glomerular Diseases: Management, Evolving Strategies, and Practice-Changing Advances
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Glenn, Dorey A., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Liu, Qian, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Greenbaum, Larry A., Children's Healthcare of Atlanta Inc, Atlanta, Georgia, United States
- Bomback, Andrew S., Columbia University, New York, New York, United States
- Mariani, Laura H., University of Michigan, Ann Arbor, Michigan, United States
- Hogan, Susan L., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Premkumar, Lakshmanane, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Centeno Cuadra, Edwing Daniel, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Bunch, Donna O., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Mottl, Amy K., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Denburg, Michelle, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Zee, Jarcy, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Falk, Ronald, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Background
Influenza infections contribute to healthcare utilization and morbidity in patients with glomerular disease (GD), and immunogenicity may be attenuated by GD activtiy and immunosuppressant use.
Methods
We evaluated immunogenicity of influenza vaccines among patients with GD in CureGN. Antibody titers to 6 influenza strains were measured by quantitative multiplex bead assay within 6 months before (V0) and 1-4 months (V1) after vaccination. Seroprotection was defined as effective dilution (ED50) ≥3.76 on any strain. Univariate associations of seroprotection at V1 with demographics/clinical characteristics were examined among those not seroprotected at V0. Time to first respiratory or multisystem infection was compared using a log-rank test.
Results
114 individuals were included. Among 79 not seroprotected at V0, 53 (67%) did not achieve seroprotection at V1 (non-response). Among responders and non-responders, 62% and 58% had immunosuppression within 2 weeks of vaccination, respectively, including 8% and 15% with anti-CD20 therapy. Non-White race, Hispanic/Latino ethnicity, and comorbidity burden were significantly associated with non-response (p=0.015, 0.013, and <0.001). IgAN/IgAV was over-represented among responders (50% vs. 21%, p=0.053). Immunosuppressant use, eGFR, proteinuria, total IgG, and serum albumin were not associated with response (Table 1). 8% (4/53, 3.2/100 person-years) of non-responders and 8% (2/26, 2.9/100 person-years) of responders had infections. Infection-free survival did not differ significantly between groups over 3 years (p=0.88).
Conclusion
Seroprotection following influenza vaccination was poor in patients with GD, with notable disparities by race and ethnicity. Although infection-free survival did not differ significantly by seroprotection, the small sample size may limit power to detect clinically meaningful differences.
Acknowledgment
Data provided by NIDDK CR, a program of the National Institute of Diabetes and Digestive and Kidney Diseases
Funding
- NIDDK Support